Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Safety of the Use of doTBal (Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program

NCT04916899 is registered in ClinicalTrials.gov with Laboratorios Silanes S.A. de C.V. as lead sponsor.

NCT NCT04916899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04916899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Safety of the Use of doTBal (Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program
Lead sponsor
Laboratorios Silanes S.A. de C.V.
Phase
Observational
Overall status
Completed
Start date
November 30, 2014
Completion date
September 30, 2016
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis